第 三 ヶ月 の 薬剤 による 中絶: 貧血 と 失血
Lucy Rose1, Sarah Putnam2, Eve Espey1
1Department of Obstetrics and Gynecology, University of New Mexico.
Current opinion in obstetrics & gynecology
|September 2, 2025
まとめ
薬による中絶はほとんどの場合安全ですが,貧血患者での使用に関するデータは限られています. 安全なヘモグロビンレベルを確立し,すべての人に治療のアクセスを改善するには,さらなる研究が必要です.
科学分野:
- 生殖 健康
- 血液学
- 医療に関するガイドライン
背景:
- 薬による中絶は広く用いられ 安全で有効であることが証明されています
- 薬による妊娠中絶の安全性に関するデータは限られている.
- 薬による中絶による量的な失血データは少ない.
研究 の 目的:
- 薬物中絶における貧血と失血に関する現在のガイドラインと文献をレビューする.
- 貧血患者の中絶に関する臨床実務と将来の研究を参考にすること.
主な方法:
- 薬物中絶に関する現在のガイドラインと研究の文献レビュー.
- 薬物中絶の研究で報告された血流の分析
- 研究集団におけるヘモグロビン値と妊娠期間の検査
主要な成果:
- 現在のガイドラインには 妊娠中絶のための安全なヘモグロビン値が 定められていない.
- 研究では,薬による中絶ではヘモグロビンの減少が最小値 (0. 1- 0. 7 g/ dl) であることを示しています.
- ほとんどの研究では,著しい貧血または後期妊娠期間を有する個体を除外しています.
結論:
- 貧血は中絶の制限に直面する集団に不釣り合いの影響を及ぼします.
- ガイドラインの任意のヘモグロビンのカットオフは,ケアへの障壁を生み出します.
- 中等から重度の貧血および妊娠63日以内の薬による中絶の安全性については,さらなる研究が必要である.
関連する概念動画
01:07Teratogenicity
2.7K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.7K
01:19Rh Blood Group
1.8K
The Rhesus (Rh) antigen is crucial in determining blood groups and ensuring compatibility during blood transfusions.
1.8K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
01:27Ovarian Cycle
1.8K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.8K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
321
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
321